Comparative effectiveness of CAR-T cell therapy and CD20xCD3 bispecific antibodies in relapsed/refractory follicular lymphoma: A propensity score–matched real-world analysis.
639 Background: CD20×CD3 bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy have expanded treatment options for relapsed/refractory follicular lymphoma (R/R FL). Although both therapies demonstrate substantial clinical activity, comparative real-world data remain limited. We compared sur...